nach oben

Erschienen in:

11.01.2018 | Interesting Image

Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept

verfasst von: Richard P. Baum, Thomas Langbein, Aviral Singh, Mostafa Shahinfar, Christiane Schuchardt, Gerd Fabian Volk, Harshad Kulkarni

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

The dose-limiting salivary gland toxicity of ²²⁵Ac-labelled PSMA for treatment of metastatic, castration-resistant prostate cancer remains unresolved. Suppressing the metabolism of the gland by intraparenchymal injections of botulinum toxin appears to be a promising method to reduce off-target uptake. A ⁶⁸Ga-PSMA PET/CT scan performed 45 days after injection of 80 units of botulinum toxin A into the right parotid gland in a 63-year-old patient showed a decrease in the SUVmean in the right parotid gland of up to 64% as compared with baseline. This approach could be a significant breakthrough for radioprotection of the salivary glands during PSMA radioligand therapy.

Rodwell K, Edwards P, Ware RS, Boyd R. Salivary gland botulinum toxin injections for drooling in children with cerebral palsy and neurodevelopmental disability: a systematic review. Dev Med Child Neurol. 2012;54:977–87.CrossRefPubMed

Reddihough D, Erasmus CE, Johnson H, McKellar GMW, Jongerius PH. Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement. Eur J Neurol. 2010;17(Suppl 2):109–21.CrossRefPubMed

Teymoortash A, Pfestroff A, Wittig A, Franke N, Hoch S, Harnisch S, et al. Safety and efficacy of Botulinum toxin to preserve gland function after radiotherapy in patients with head and neck cancer: a prospective, randomized, placebo-controlled, double-blinded phase I clinical trial. PLoS One. 2016;11:e0151316.CrossRefPubMedPubMedCentral

Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624–31.CrossRefPubMed

Kratochwil C, Schmidt K, Afshar-Oromieh A, Bruchertseifer F, Rathke H, Morgenstern A, et al. Targeted alpha therapy of mCRPC: dosimetry estimate of (213)bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2018;45:31–7.CrossRefPubMed

Titel: Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept
verfasst von: Richard P. Baum
Thomas Langbein
Aviral Singh
Mostafa Shahinfar
Christiane Schuchardt
Gerd Fabian Volk
Harshad Kulkarni
Publikationsdatum: 11.01.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Nuclear Medicine and Molecular Imaging / Ausgabe 1/2018
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-017-0508-3

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

PERCIST in Perspective

Obesity and Brain Positron Emission Tomography

Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies

Multiple Regression Analysis of Predictors of Bone Scintigraphy Positivity in Patients with Head and Neck Cancers

Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?

Prognostic Value of Pre- and Post-Treatment FDG PET/CT Parameters in Small Cell Lung Cancer Patients